Claims for Patent: 8,715,985

Summary for Patent: 8,715,985

Title:	Clostridium histolyticum recombinant collagenases and method for the manufacture thereof
Abstract:	The present invention relates to the production of recombinant collagenases, and in particular describes a method for the production of recombinant Clostridium histolyticum collagenases CoI characterized by a yield higher than approximately 140 mg/l of culture of said collagenases in soluble and biologically active form, collagenases produced by this method, compositions comprising these collagenases and the use thereof.
Inventor(s):	Bertuzzi; Federico (Milan, IT), Cuttitta; Angela (Palermo, IT), Ghersi; Giulio (Palermo, IT), Mazzola; Salvatore (Palermo, IT), Salamone; Monica (Palermo, IT), Seidita; Gregorio (Palermo, IT)
Assignee:	Abiel S.R.L. (Campobello, IT)
Application Number:	13/515,203
Patent Claims:	1. A method for production of a recombinant C. histolyticum collagenase comprising: a) designing an optimized nucleotide sequence for expression of said recombinant C. histolyticum collagenase, wherein said optimized nucleotide sequence is SEQ ID NO: 1 or SEQ ID NO: 3; b) introducing, in an inducible expression vector, a nucleotide sequence coding for a fusion protein, wherein said nucleotide sequence comprises said optimized sequence fused to a purification tag coding sequence and a soluble polypeptide coding sequence, and wherein said nucleotide sequence is operatively linked to an inducible promoter sequence, a transcription start sequence, and a termination sequence; c) transforming a bacterial strain defective in expression of endogenous proteases with said expression vector; d) culturing said transformed bacterial strain at a temperature in a range from 28.degree. C. to 32.degree. C.; e) inducing expression of said fusion protein by adding a suitable inductor in said bacterial strain; f) extracting the fusion protein from the induced bacterial strain; and g) purifying said fusion protein; wherein said method provides a yield higher than 140 mg/l of culture of said recombinant C. histolyticum collagenase in soluble and enzymatically active form. 2. The method according to claim 1, wherein said temperature is about 30.degree. C. 3. The method according to claim 1, wherein said optimized sequence is fused to said soluble polypeptide coding sequence through a binding sequence coding for at least one cleavage site for a suitable proteolytic enzyme and further comprising: h) obtaining said recombinant C. histolyticum collagenase by enzymatically cleaving said at least one cleavage site. 4. The method according to claim 1, wherein said recombinant C. histolyticum collagenase is a fusion protein MBP-C. histolyticum ColG or MBP-C. histolyticum ColH. 5. The method according to claim 3, wherein said recombinant C. histolyticum collagenases is C. histolyticum ColG collagenase or C. histolyticum ColH collagenase. 6. The method according to claim 1, wherein said expression vector is selected from the group consisting of the vector classes: pMAL, pRSET, pTAC, pFLAG, pET, and pT7. 7. The method according to claim 6, wherein said expression vector of the pMAL class is vector pMAL-c2X and said expression vector of the pRSET class is vector pRSET-A. 8. The method according to claim 1, wherein said vector further comprises one or more control sequences operatively linked to said fusion protein selected from the group consisting of an enhancer sequence, a ribosome binding site, a sequence coding for a repressor, an operator sequence, a polyadenylation sequence, and a replication origin. 9. The method according to claim 1, wherein said "purification tag" is selected from the group consisting of: poly/hexahistidine tag, glutathione-S-transferase (GST), maltose binding protein (MBP), thioredoxin, protein A fragment of Staphylococcus aureus (ZZ), peptide with affinity for streptavidin (Strep-tag), and flag peptide. 10. The method according to claim 1, wherein said bacterial strain is selected from the group consisting of lysogen Escherichia coli strains from D3 series, Escherichia coli strains with a Ion and/or ompT and/or dnaJ genotype, and BL21, BL21 AI, C600, CJ236, GC5, GM48, HB101, JM83, JM101, JM103, JM105, JM107, JM109, JM110, K802, LE392, MC1061, MM294, NM477, NM522, NM554, NM621, RR1, .chi.1776, Rosetta(DE3)pLysS, DH5.alpha., DH10B, ER2566, CAG597, CAG629, ER2508, UT5600, CAG626, PR1031, KS1000, ER2507, and TB1 Escherichia coli strains. 11. The method according to claim 1, wherein said inductor is (i) isopropyl .beta.-D-1-thiogalactopyranoside (IPTG) for an expression vector of pMAL, pGEX, pTAC or pFLAG class, or (ii) arabinose for an expression vector of pRSET, pET or pT7 class in the BL21-AI strain. 12. A recombinant C. histolyticum collagenase, characterised in that cells extracted with said recombinant C. histolyticum collagenase maintain a differentiated phenotype; wherein said recombinant C. histolyticum collagenase is produced by a method comprising: a) designing a nucleotide optimized sequence for expression of said recombinant C. histolyticum collagenase, wherein said optimized nucleotide sequence is SEQ ID NO: 1 or SEQ ID NO: 3, b) introducing, in an inducible expression vector, a nucleotide sequence coding for a fusion protein, wherein said nucleotide sequence comprises said optimized sequence fused to a soluble polypeptide coding sequence through a binding sequence coding for at least one cleavage site for a suitable proteolytic enzyme and wherein said nucleotide sequence is operatively linked to an inducible promoter sequence, a transcription start sequence, and a termination sequence; c) transforming a bacterial strain defective in expression of endogenous proteases with said expression vector, d) culturing said transformed bacterial strain at a temperature in a range from 28.degree. C. to 32.degree. C., e) inducing expression of said fusion protein by adding a suitable inductor in said bacterial strain, f) extracting the fusion protein from the induced bacterial strain, g) purifying said fusion protein, and h) obtaining said recombinant C. histolyticum collagenase by enzymatically cleaving said at least one cleavage site; wherein said method provides a yield higher than 140 mg/l of culture of said recombinant C. histolyticum collagenase is soluble and enzymatically active form. 13. The recombinant C. histolyticum collagenase according to claim 12, wherein said recombinant C. histolyticum collagenase is C. histolyticum ColG collagenase or C. histolyticum ColH collagenase. 14. A recombinant C. histolyticum collagenase encoded by the nucleotide sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 3, wherein said collagenase is in the form of an MBP-Col fusion protein having a yield higher than 140 mg/l of culture of said recombinant C. histolyticum collagenase in soluble and enzymatically active form. 15. The recombinant C. histolyticum collagenase according to claim 14, wherein said fusion protein MBP-C. histolyticum ColG or MBP-C. histolyticum ColH. 16. A recombinant C. histolyticum collagenase in the form of an MBP-Col fusion protein having a yield higher than 140 mg/l of culture of said recombinant C. histolyticum collagenase in soluble and enzymatically active form which is obtained by the method according to claim 1. 17. A composition comprising one or more recombinant C. histolyticum collagenases according to claim 12 and a suitable excipient. 18. A kit for extraction of stem and/or somatic living cells from tissues comprising one or more aliquots of the recombinant C. histolyticum collagenase according to claim 12 and one or more aliquots of reagents for extraction of said cells. 19. The kit according to claim 18, wherein said reagents suitable for the extraction comprise neutral proteases and/or thermolysin. 20. A method of using a composition comprising one or more recombinant C. histolyticum collagenases according to claim 12, the method comprising extracting stem and/or somatic living cells from a tissue with said collagenase or said composition. 21. The method according to claim 20, wherein said extraction results in isolation of living islets of Langherans from pancreas. 22. The recombinant C. histolyticum collagenase according to claim 13, wherein the number of living cells with normal phenotype extracted with recombinant C. histolyticum ColG collagenase is at least of about 7.4.times.10.sup.5 cells/ml and the number of living cells with normal phenotype extracted with recombinant C. histolyticum ColH collagenase is at least of about 8.2.times.10.sup.5 cells/ml in the in vitro extraction assay.

Details for Patent 8,715,985

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2029-12-15